Evidence map›Paper›PMID 40709592›Full record

ArticleJournal of global health2025

Artificial intelligence for tuberculosis control: a scoping review of applications in public health.

Sonia Menon, Kobto Ghislain Koura

Abstract readScoping Review
In one paragraph

Article in Journal of global health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Sonia MenonInternational Union against Tuberculosis and Lung Disease, Paris, France.
Kobto Ghislain KouraInternational Union against Tuberculosis and Lung Disease, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Artificial intelligence (AI) has become an important tool in global health, improving disease diagnosis and management. Despite advancements, tuberculosis (TB) remains a public health challenge, particularly in low- and middle-income countries where diagnostic methods are limited. In this scoping review, we aim to examine the potential role of AI in TB control. Methods: We conducted a search on 25 August 2024 for the past five years, in the PubMed database using keywords related to AI and TB. We included laboratory-based and observational studies focussing on AI applications in TB, excluding non-original research. Results: There were 34 eligible studies, identifying eight overarching aspects associated with TB control, including active case finding (ACF), triage, pleural effusion diagnosis, multidrug-resistant (MDR) TB and extensively drug-resistant (XDR) TB, differential diagnosis distinguishing active TB from TB infection and other pulmonary communicable diseases, TB and other pulmonary communicable and non-communicable diseases (NCDs), treatment outcome prediction, pleural effusion, and predictions of regional and national trends. AI may transform TB control through enhanced ACF methods and triage, improving detection rates in high-burden regions. With high accuracy, AI may diagnose pleural diagnosis, differentiate TB active and TB infection, TB and non-tuberculous mycobacterial lung disease, COVID-19, and pulmonary NCDs. AI applications may facilitate the prediction of treatment success and adverse effects. Furthermore, AI-driven hotspot mapping may identify undiagnosed TB cases at rates surpassing traditional notification methods. Lastly, predictive modelling and clinical decision support systems may improve the management of MDR-TB. Conclusions: This scoping review highlights the potential of AI-driven predictions in national TB programmes to enhance diagnostics, track trends, and strengthen public health surveillance. While promising for reducing transmission and supporting TB care in low-resource settings, these models require large-scale validation to ensure real-world applicability, especially for high-risk groups.

Indexed as

Artificial IntelligencePublic HealthTuberculosisGlobal HealthHumans

Identifiers

PMID40709592
PMCPMC12290985

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.